J. Hocke

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.

E. Van Cutsem, J. Tabernero, T. Yoshino, 2016, Clinical colorectal cancer.

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment

J. Tabernero, T. Yoshino, E. Cutsem, 2015 .

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma

Tae-You Kim, Y. Chao, C. Yen, 2018, Liver Cancer.

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

T. Giessmann, P. Stopfer, S. Wind, 2014, Clinical Drug Investigation.

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

T. Meyer, C. Yen, A. Cheng, 2017, Liver international : official journal of the International Association for the Study of the Liver.

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

T. Meyer, J. Graham, P. Ross, 2018, British Journal of Cancer.

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.

Ying Cheng, R. Kaiser, J. von Pawel, 2015, Lung cancer.

gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

H. Lenz, J. Tabernero, F. Ciardiello, 2016 .

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.

T. Meyer, C. Yen, A. Cheng, 2016 .

Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

T. Meyer, J. Graham, P. Ross, 2015 .